Compare NRG Energy Inc (NRG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? NRG Energy Inc trades at $116.71 (market cap $25.15B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: NRG Energy Inc pays a 1.59% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, NRG Energy Inc nearer its low. Which is the better fit depends on your goals.
| NRG | XBI | |
|---|---|---|
Market Cap | $25.15B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $184.03 | $169.55 |
52-Week Low | $109.51 | $93.43 |
Enterprise Value | $49.10B | — |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $119.64, up 0.52% on the day, with a bullish technical signal and key support at $118. Recent Q2 2026 earnings missed estimates, but revenue grew 11% year-over-year. The company is pursuing growth via a 1.2 GW Texas data center power project and reaffirmed 2026 guidance, while analyst consensus remains strongly positive with a $201.29 price target.
The outlook is supported by strategic investments in data center demand and shareholder returns, but risks include rising interest costs, high leverage, and execution challenges. The stock offers significant upside to analyst targets if growth initiatives deliver, though near-term volatility may persist amid earnings misses and macroeconomic pressures.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
